Endocrine Abstracts

Denosumab is a monoclonal antibody against RANKL used in the treatment of postmenopausal osteoporosis. RANK/RANKL/OPG cycle is effective on both immune system and osteoporosis. Some RANK mutations are associated with hypogammaglobulinaemia. There are studies suggesting that the RANK/RANKL pathway may mediate the development of insulin resistance and hepatosteatosis. However, the clinical effects of denosumab on inflammation and immunity are not well known. In this study, we ai...